Compare Globus Medical Inc. Class A Common Stock (GMED) vs WisdomTree Inc. Common Stock (WT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs WisdomTree Inc. Common Stock — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while WisdomTree Inc. Common Stock trades at $21.02 (market cap $3.27B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 3.1× WisdomTree Inc. Common Stock's market cap, and WisdomTree Inc. Common Stock pays a 0.56% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and WisdomTree Inc. Common Stock for 6 Days on average.
| GMED | WT | |
|---|---|---|
Market Cap | $10.25B | $3.27B |
Volume | 1,108,124 | 2,488,313 |
Sector | Health | Financials |
52-Week High | $96.82 | $25.04 |
52-Week Low | $58.33 | $10.73 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $9.76B | $4.02B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
WisdomTree (WT) trades at $21.61, down 2.83% on the day, near the analyst low target of $21.30. The stock shows bearish technical signals with mixed oscillators, while fundamentals reveal strong profitability margins and consistent earnings beats. Recent news highlights WisdomTree's expansion into tokenized funds and new ETF launches, signaling growth initiatives.
The outlook is cautiously optimistic given analyst consensus favoring Buy ratings and a $26.05 price target, but risks include high valuation multiples and negative investing cash flow trends. Earnings momentum from recent beats supports upside potential, though investors face volatility from market sentiment and execution risks in new business lines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About WisdomTree Inc. Common Stock
WisdomTree provides exchange-traded products, model portfolios, and digital-asset-related products and services. Its digital offerings include tokenized funds, an institutional platform, and a blockchain-native wallet.
Read more on WT →
